{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:55:20Z","timestamp":1774529720267,"version":"3.50.1"},"reference-count":25,"publisher":"The Endocrine Society","issue":"4","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hypoparathyroidism management has advanced in recent decades, particularly for patients unresponsive to conventional therapy. Several parathyroid hormone\u2013based agents have been developed to better imitate physiologic hormone replacement. Recombinant human parathyroid hormone (1-84) [rhPTH(1-84), Natpar\u00ae] was approved as an adjunct to calcium and vitamin D for chronic hypoparathyroidism but was later withdrawn, with global production ceasing in 2024. Palopegteriparatide (Yorvipath\u00ae; TransCon PTH), a long-acting parathyroid hormone (1-34) prodrug recently approved, represents a new-generation replacement therapy. Transitioning patients from rhPTH(1-84) to palopegteriparatide is increasingly relevant but remains scarcely documented, with only a single real-world report available. We describe a patient with chronic postsurgical hypoparathyroidism after total thyroidectomy who continued to experience symptoms despite conventional therapy. rhPTH(1-84) initially improved symptoms and stabilized calcium levels, but additional supplementation became necessary over time. In September 2024, ahead of rhPTH(1-84) withdrawal, therapy was switched to palopegteriparatide, allowing gradual dose titration and complete withdrawal of calcium and magnesium supplements. The patient maintained stable biochemical values and reported improved well-being, with no adverse events. This case supports the effective transition from rhPTH(1-84) to palopegteriparatide, restoring biochemical stability and independence from conventional therapy.<\/jats:p>","DOI":"10.1210\/jcemcr\/luag048","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:01:31Z","timestamp":1774526491000},"source":"Crossref","is-referenced-by-count":0,"title":["Successful transition from rhPTH(1-84) to palopegteriparatide in chronic hypoparathyroidism"],"prefix":"10.1210","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2327-1659","authenticated-orcid":false,"given":"Isabella","family":"Chiardi","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Therapeutics, University of Pavia , Pavia 27100 ,","place":["Italy"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2125-4937","authenticated-orcid":false,"given":"Pierpaolo","family":"Trimboli","sequence":"additional","affiliation":[{"name":"Thyroid Unit, Clinic for Endocrinology and Diabetology, Ente Ospedaliero Cantonale (EOC) , Bellinzona 6500 ,","place":["Switzerland"]},{"name":"Faculty of Biomedical Sciences, Universit\u00e0 Della Svizzera Italiana , Lugano 6900 ,","place":["Switzerland"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"issue":"10","key":"2026032608012622700_luag048-B1","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1002\/jbmr.483","article-title":"Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research","volume":"26","author":"Bilezikian","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2026032608012622700_luag048-B2","doi-asserted-by":"crossref","first-page":"e210379","DOI":"10.1530\/EC-21-0379","article-title":"Low health-related quality of life in Hypoparathyroidism and need for PTH analog","volume":"11","author":"Kontogeorgos","year":"2022","journal-title":"Endocr Connect"},{"issue":"4","key":"2026032608012622700_luag048-B3","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1007\/s12325-021-01649-2","article-title":"Risk of Nephrolithiasis and Nephrocalcinosis in patients with chronic Hypoparathyroidism: a retrospective cohort study","volume":"38","author":"Ketteler","year":"2021","journal-title":"Adv Ther"},{"issue":"1","key":"2026032608012622700_luag048-B4","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s40520-025-03139-9","article-title":"Bone status in patients with chronic Hypoparathyroidism: results from the Italian HypoparaNET database","volume":"37","author":"Marini","year":"2025","journal-title":"Aging Clin Exp Res"},{"issue":"11","key":"2026032608012622700_luag048-B5","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1002\/jbmr.1979","article-title":"Cardiovascular and renal complications to postsurgical Hypoparathyroidism: a Danish nationwide controlled historic follow-up study","volume":"28","author":"Underbjerg","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2026032608012622700_luag048-B6","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/jbmr.2273","article-title":"Postsurgical Hypoparathyroidism\u2013risk of fractures, psychiatric diseases, cancer, cataract, and infections","volume":"29","author":"Underbjerg","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2026032608012622700_luag048-B7","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/jbmr.2501","article-title":"The epidemiology of nonsurgical Hypoparathyroidism in Denmark: a nationwide case finding study","volume":"30","author":"Underbjerg","year":"2015","journal-title":"J Bone Miner Res"},{"key":"2026032608012622700_luag048-B8","author":"Takeda"},{"issue":"2","key":"2026032608012622700_luag048-B9","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s12020-023-03355-1","article-title":"Continuous subcutaneous rhPTH infusion for managing difficult chronic Hypoparathyroidism. A systematic review","volume":"81","author":"Gamarra","year":"2023","journal-title":"Endocrine"},{"key":"2026032608012622700_luag048-B10","doi-asserted-by":"crossref","first-page":"e931739","DOI":"10.12659\/AJCR.931739","article-title":"Continuous teriparatide treatment in chronic Hypoparathyroidism: a case report","volume":"22","author":"Saraiva","year":"2021","journal-title":"Am J Case Rep"},{"issue":"5","key":"2026032608012622700_luag048-B11","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/j.eprac.2023.03.131","article-title":"Abstract #1407986: abaloparatide administration through the simplicity patch: a therapeutic option for refractory Hypoparathyroidism post-thyroidectomy","volume":"29","author":"Chamseddin","year":"2023","journal-title":"Endocr Pract"},{"issue":"8","key":"2026032608012622700_luag048-B12","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/jbmr.4016","article-title":"A randomized double-blind placebo-controlled first-in-human phase 1 trial of TransCon PTH in healthy adults","volume":"35","author":"Karpf","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2026032608012622700_luag048-B13","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1002\/jbmr.3824","article-title":"Design and preclinical development of TransCon PTH, an investigational sustained-release PTH replacement therapy for Hypoparathyroidism","volume":"34","author":"Holten-Andersen","year":"2019","journal-title":"J Bone Miner Res"},{"key":"2026032608012622700_luag048-B14","author":"Ascendis Pharma"},{"key":"2026032608012622700_luag048-B15","author":"Ascendis Pharma"},{"key":"2026032608012622700_luag048-B16","author":"Teijin Pharma Limited"},{"issue":"4","key":"2026032608012622700_luag048-B17","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1210\/clinem\/dgae693","article-title":"Efficacy and safety of TransCon PTH in adults with Hypoparathyroidism: 52-week results from the phase 3 PaTHway trial","volume":"110","author":"Clarke","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026032608012622700_luag048-B18","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1007\/s12325-024-02843-8","article-title":"Palopegteriparatide treatment improves renal function in adults with chronic Hypoparathyroidism: 1-year results from the phase 3 PaTHway trial","volume":"41","author":"Rejnmark","year":"2024","journal-title":"Adv Ther"},{"issue":"1","key":"2026032608012622700_luag048-B19","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/jbmr.4726","article-title":"Efficacy and safety of parathyroid hormone replacement with TransCon PTH in Hypoparathyroidism: 26-week results from the phase 3 PaTHway trial","volume":"38","author":"Khan","year":"2023","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2026032608012622700_luag048-B20","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1002\/jbmr.4671","article-title":"The second international workshop on the evaluation and management of hypoparathyroidism","volume":"37","author":"Khan","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2026032608012622700_luag048-B21","doi-asserted-by":"crossref","first-page":"E372","DOI":"10.1210\/clinem\/dgab577","article-title":"PaTH forward: a randomized, double-blind, placebo-controlled phase 2 trial of TransCon PTH in adult Hypoparathyroidism","volume":"107","author":"Khan","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026032608012622700_luag048-B22","author":"Schwarz"},{"issue":"1","key":"2026032608012622700_luag048-B23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11914-025-00905-6","article-title":"PTH substitution therapy for chronic Hypoparathyroidism: PTH 1\u201384 and palopegteriparatide","volume":"23","author":"Palermo","year":"2025","journal-title":"Curr Osteoporos Rep"},{"issue":"12","key":"2026032608012622700_luag048-B24","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.eprac.2025.08.008","article-title":"Early U.S. Real-world treatment patterns and outcomes in palopegteriparatide treatment for patients with Hypoparathyroidism","volume":"31","author":"Graham","year":"2025","journal-title":"Endocr Pract"},{"issue":"9","key":"2026032608012622700_luag048-B25","doi-asserted-by":"crossref","first-page":"bvaf113","DOI":"10.1210\/jendso\/bvaf113","article-title":"Switch from rhPTH1-84 to TransCon PTH with individual dose adjustment in adult Hypoparathyroidism\u20144-week results","volume":"9","author":"Siggelkow","year":"2025","journal-title":"J Endocr Soc"}],"container-title":["JCEM Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/4\/luag048\/67550055\/luag048.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcemcr\/article-pdf\/4\/4\/luag048\/67550055\/luag048.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:01:34Z","timestamp":1774526494000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcemcr\/article\/doi\/10.1210\/jcemcr\/luag048\/8541556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3,19]]}},"URL":"https:\/\/doi.org\/10.1210\/jcemcr\/luag048","relation":{},"ISSN":["2755-1520"],"issn-type":[{"value":"2755-1520","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,3,19]]},"article-number":"luag048"}}